2009•Journal watchRequires access

Predicting Response to Hepatitis B Virus Therapy

Atif Zaman

Abstract

Hepatitis B virus surface antigen (HBsAg) loss and, ultimately, seroconversion to hepatitis B surface antibodies might be the only indicator of true clearance of hepatitis B virus (HBV) in chronically infected patients. Pegylated interferon (PEG-IFN) alfa-2a–based therapy can induce HBsAg seroconversion in some hepatitis B e antigen (HBeAg)-negative patients. Now two groups of researchers have examined the usefulness of HBsAg levels during and after HBV therapy as predictors of treatment response to PEG-IFN. Moucari and colleagues prospectively evaluated 48 patients with HBeAg-negative …

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: HBsAg, Medicine, HBeAg, Seroconversion, Hepatitis B virus, Virology, Pegylated interferon, Immunology